Saptagir Laboratories has entered into an exclusive agreement with Jubilant Generics, a Jubilant Life Sciences company, to manufacture intermediates and active pharmaceutical ingredients (APIs) used for intravenously-administered drug Remdesivir.
The drug will be produced at its World Health Organisation (WHO) Good Manufacturing Practices (GMP)-certified sterile drug product manufacturing plant at Hyderabad, acquired for ₹75 crore.
“This partnership is timely and in line with our strategic growth plans for the company. Our foray into bulk drugs manufacturing will open new revenue streams,” Shilpa Reddy, Promoter and Managing Director, Saptagir Laboratories, said in a release issued on Monday.
Dr Reddy’s launches Remdesivir as Redyx in India
Remdesivir is an experimental antiviral drug developed by Gilead Sciences Inc. as a course of treatment for Covid-19. Gilead entered into a non-exclusive licensing agreement with Jubilant Life Sciences for distribution to 127 countries.
Following this, Jubilant Life Sciences, through its subsidiary Jubilant Generics, entered into an exclusive agreement with Saptagir Laboratories to manufacture Remdesivir.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.